" /> Ublituximab - CISMeF





Preferred Label : Ublituximab;

NCIt synonyms : Ublituximab-xiiy;

NCIt definition : A chimeric recombinant IgG1 monoclonal antibody directed against human CD20 with potential antineoplastic activity. Ublituximab specifically binds to the B cell-specific cell surface antigen CD20, thereby potentially inducing a B cell-directed complement dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) against CD20-expressing B cells, leading to B cell apoptosis. CD20 is a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B cells during most stages of B cell development and is often overexpressed in B-cell malignancies. Ublituximab has a specific glycosylation profile, with a low fucose content, that may enhance its ADCC response against malignant B cells.;

UNII : U59UGK3IPC;

CAS number : 1174014-05-1;

Drug name : Briumvi;

Molecule name : LFB-R603; TG-20; TGTX-1101; TG-1101; LFB R603; TGTX 1101; TG 1101; TG 20;

Codes from synonyms : 520;

Details


You can consult :


Nous contacter.
08/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.